CHMP says yes to developing world vaccine, Novartis' Seebri Breezhaler, Takeda's Revestive
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's scientific committee, the CHMP, has given the green light for the European Commission to OK a number of new medicines, including Takeda's orphan drug Revestive (teduglutide) for patients with short bowel syndrome. And, for the first time ever, it recommended a vaccine – Sanofi Pasteur's Hexaxim – for use in markets outside the EU.